LNG01 (formerly SM04646) is a Phase I development-stage small-molecule inhibitor of the Wnt signaling pathway for the treatment of idiopathic pulmonary fibrosis (IPF). LNG01 is a nebulized therapy, which has been shown to be safe in healthy volunteers and subjects with IPF in single ascending dose (SAD) and multiple ascending dose (MAD) studies respectively. (UT in-licensed NA rights for SM04646 from Samumed in 2018).
Samumed’s small molecule Wnt pathway inhibitor, SM04646, has demonstrated anti-fibrotic properties in multiple in vitro and in vivo models. SM04646 could be the first inhaled, potentially disease-modifying therapy for IPF patients.